|Dr. John K. A. Prendergast||Co-Founder & Independent Non-Exec. Chairman||97.5k||N/A||1954|
|Dr. Carl Spana||Co-Founder, Pres, CEO & Director||867.62k||N/A||1962|
|Mr. Stephen T. Wills CPA, CPA, MST||CFO, COO, Exec. VP, Treasurer & Sec.||797.21k||N/A||1957|
|Burns McClellan||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Stephen A. Slusher Esq.||Chief Legal Officer||N/A||N/A||N/A|
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Palatin Technologies, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 4. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 4.